Zonisamide for Canine Idiopathic Epilepsy: Efficacy, Tolerability, and Therapeutic Drug Monitoring

Bottom line

• Zonisamide (ZNS) is a sulfonamide-derived, newer-generation antiseizure medication used off-label in canine idiopathic epilepsy (IE). As of July 2026, the largest dataset — a 207-dog retrospective therapeutic-drug-monitoring (TDM) cohort — reports 59% responders on monotherapy [1].
• In a prospective multicenter trial of 56 newly-diagnosed, ASM-naive dogs, 76% (40/53 evaluable) achieved a ≥50% reduction in seizure frequency and 55% (29/53) achieved seizure freedom over 12 weeks of monotherapy [2].
• An evidence-based canine TDM reference interval of 10–55 mcg/mL is proposed [1] — broader than the human interval of 10–40 mcg/mL; responder mean trough was 18.9 mcg/mL (range 8.0–48.0) in the prospective cohort [2].
• Adverse effects in dogs are generally mild and transient (13% incidence; no discontinuations, no clinically relevant lab changes) [2]; idiosyncratic hepatotoxicity and renal tubular acidosis are described in review/case literature but were not quantified in these trials.
• Feline evidence is thinner and retrospective: a 57-cat multicenter cohort found a median decrease of one seizure/month (P = .001) with a distinct AE pattern (sedation and hyporexia each 17%) [3]. ZNS is not FDA-approved for veterinary use in the U.S. — dose from a current formulary, not from any figure here.

Drug facts

• Class / MOA — Sulfonamide-derived antiseizure medication. Blocks voltage-gated sodium channels and T-type calcium channels; may enhance GABAergic activity. Broad, non-benzodiazepine mechanism.
• Primary indication (veterinary) — Monotherapy or adjunctive therapy for canine idiopathic (non-structural) epilepsy; off-label consideration in cats when phenobarbital is unsuitable or insufficient [3].
• Human labeling — Approved as adjunctive therapy for partial seizures in humans; the veterinary use described here is entirely off-label.
• Dosing / PK — Relatively predictable, approximately linear pharmacokinetics support once- or twice-daily dosing; individual clearance variation makes TDM valuable for dose optimization [1]. Exact mg/kg starting doses and titration steps are formulary matters (e.g., Plumb's) and are intentionally out of scope here.
• Approval status — Not FDA-approved for dogs or cats in the United States.
• Key contraindications / cautions — Sulfonamide hypersensitivity; pre-existing hepatic or renal compromise warrants caution given reported idiosyncratic hepatotoxicity and renal tubular acidosis. Establish baseline chemistry/CBC and monitor periodically.

Does zonisamide work? Efficacy in canine idiopathic epilepsy

Two complementary JVIM datasets frame current canine efficacy, one retrospective (long-horizon, real-world) and one prospective (newly-diagnosed, protocolized).

The 207-dog retrospective cohort (Thungrat et al., a decade of Auburn University TDM data, 2011–2021) is the largest ZNS monotherapy efficacy dataset [1]. Dogs with non-structural epilepsy were classified by International Veterinary Epilepsy Task Force (IVETF) response categories: 59% (n=123) were responders — 29% achieving seizure freedom (category 1) and 30% partial response (category 2) — while 41% (n=84) were non-responders (category 3; between-group difference P < .01). Because the cohort is retrospective TDM-library-derived, it characterizes real-world responders rather than a controlled efficacy estimate.

The 56-dog prospective multicenter open-label trial (Saito et al., Japan; all ASM-naive, ≥2 seizures in 12 weeks) provides the cleaner newly-diagnosed signal [2]. Over 12 weeks, 76% (40/53 evaluable) achieved ≥50% seizure reduction and 55% (29/53) achieved seizure freedom. These figures are broadly consistent with what is reported for phenobarbital as first-line monotherapy, though the study was uncontrolled.

Neutral synthesis: the two designs converge on a responder rate in the ~59–76% range, with the higher end reflecting a protocolized, treatment-naive population and the lower end reflecting a broad real-world cohort that includes harder-to-control and longer-followed dogs. Neither is a randomized comparative trial, so the numbers bound expectations rather than rank ZNS against alternatives.

How does zonisamide compare to phenobarbital and other first-line ASMs?

Direct head-to-head canine trials are limited, so comparison rests on cross-study inference and tolerability profile rather than on randomized data.

• Efficacy — ZNS responder rates (59–76% [1][2]) are in the same range commonly cited for phenobarbital first-line monotherapy, but no prospective randomized comparison establishes superiority or non-inferiority.
• Safety trade-off — The principal differentiator is the AE profile. Phenobarbital carries recognized dose-dependent hepatotoxicity risk with chronic administration; ZNS showed no clinically relevant chemistry/haematology changes in the prospective dog cohort [2]. This favors ZNS as a consideration where hepatic risk is a concern — with the caveat that idiosyncratic ZNS hepatotoxicity still occurs and prospective comparative safety data are lacking.
• Where it sits — ZNS is used first- or second-line as monotherapy and as add-on in refractory cases. For sibling first-line agents with their own approval and evidence base, see the potassium bromide and imepitoin reviews.

Therapeutic drug monitoring: the proposed 10–55 mcg/mL canine reference interval

Before these studies, canine ZNS TDM lacked a validated reference interval, forcing extrapolation from the human 10–40 mcg/mL range. Thungrat et al. derived a proposed canine reference interval of 10–55 mcg/mL from responders' plasma concentrations [1] — deliberately broader than the human interval to reflect species pharmacokinetic differences and IVETF-defined response.

Supporting concentration data from the prospective cohort: responders had a mean trough of 18.9 mcg/mL (range 8.0–48.0 mcg/mL) [2], sitting comfortably inside the proposed interval. Together these give a more actionable framework than extrapolated human data alone.

Caveat on strength of evidence: the interval derives from a retrospective design, so confidence intervals are wide and the range is a starting framework, not a hard target. Use TDM to guide titration — especially in non-responders or dogs showing possible toxicity — while adjusting primarily to clinical seizure response.

Safety and adverse effects

Dogs. In the prospective 56-dog trial, AEs occurred in 7/56 (13%): reduced activity, decreased appetite, vomiting, hindlimb weakness, soft stools, or constipation [2]. All were mild and temporary; none required discontinuation, and standard chemistry/haematology showed no clinically relevant changes. Idiosyncratic reactions — hepatotoxicity and renal tubular acidosis — appear in case series and review literature but were not quantified within these trial datasets, so baseline and periodic bloodwork remains prudent.

Cats. The 57-cat retrospective cohort reported a distinct AE pattern: hyporexia (17%), sedation (17%), ataxia (11%), and emesis (5%), with a few cats developing mild nonregenerative anemia, mild metabolic acidosis, or mild increases in ALT and ALP [3]. Overall the authors judged ZNS well tolerated in most cats, but the sedation/hyporexia signal is more prominent than in the canine data and warrants explicit owner counseling and monitoring when extrapolating to feline patients.

Special populations: zonisamide in cats

Evidence-based antiseizure options in cats beyond phenobarbital remain limited, and the 57-cat multicenter retrospective cohort (Djani et al.) is one of the larger feline-specific datasets to date [3]. Across all 57 cats, oral ZNS was associated with a median decrease of one seizure per month (P = .001) and a similar reduction in seizure-days per month. In the idiopathic-epilepsy subgroup, median reductions were larger (one and two, respectively). The authors concluded ZNS was well tolerated and efficacious in controlling seizure activity in most cats.

Interpretation: the feline data are retrospective and uncontrolled — they describe association, not proven efficacy — but they support ZNS as a reasonable consideration when phenobarbital is unsuitable or insufficient. The feline AE pattern differs from dogs (above), so feline use is an extrapolation that should be paired with species-specific monitoring and formulary-derived dosing.

Contraindications, precautions & PK

• Sulfonamide hypersensitivity — ZNS is sulfonamide-derived; avoid in patients with known sulfonamide hypersensitivity.
• Hepatic reserve — Idiosyncratic hepatotoxicity is reported; obtain baseline liver enzymes and monitor. In cats, mild ALT/ALP increases were observed in a minority [3].
• Renal / acid-base — Renal tubular acidosis is described in dogs; mild metabolic acidosis was seen in some cats [3]. Consider acid-base status in at-risk patients.
• Haematology — Mild nonregenerative anemia occurred in a few cats [3]; include CBC in monitoring.
• Pharmacokinetics — Approximately linear PK with once- or twice-daily dosing; inter-individual clearance variation is the core rationale for TDM [1]. Titrate to clinical response, using trough concentrations against the proposed 10–55 mcg/mL canine interval [1] as a guide, not a mandate.
• Formulary dependence — Species-specific mg/kg dosing, monitoring intervals, and full contraindication lists belong to a current formulary (e.g., Plumb's Veterinary Drug Handbook) and are out of scope for this evidence summary.

Practical decision support

• Candidate selection — Reasonable first- or second-line monotherapy for canine IE, and a first consideration in dogs where phenobarbital hepatotoxicity risk is a concern [2]. In cats, consider when phenobarbital is unsuitable or insufficient, counseling owners on the sedation/hyporexia signal [3].
• Baseline — Chemistry (including liver enzymes) and CBC before starting; document seizure frequency to define a response denominator.
• Titration & monitoring — Adjust to clinical seizure response; use TDM to interpret non-response or suspected toxicity, referencing the proposed 10–55 mcg/mL canine interval [1] (responder mean trough ~18.9 mcg/mL [2]). Recheck bloodwork periodically per formulary.
• Setting expectations — Communicate a realistic responder range (~59–76% in dogs [1][2]) and that seizure freedom is achievable in roughly half of newly-diagnosed dogs [2] but not guaranteed.
• Escalation — For refractory cases, ZNS is used adjunctively; revisit diagnosis (structural vs idiopathic) and consider sibling agents (potassium bromide, imepitoin) within a formulary-guided plan.

Frequently Asked Questions

(Rendered from the FAQ bundle below.)

Changelog

• 2026-06-19: First published (canine evergreen).
• 2026-07-06: Consolidated two dated dispatch updates into this hub — the TDM reference-interval dispatch (Thungrat 207-dog cohort + Saito prospective trial; proposed 10–55 mcg/mL canine RI) and the feline seizure-control dispatch (Djani 57-cat retrospective cohort). Added a dedicated TDM section, a comparator section, an expanded safety section covering species-specific AE patterns, a feline special-populations section, and consolidated contraindications/PK and practical decision-support sections. Each distinct study is cited once ([1] Thungrat, [2] Saito, [3] Djani).